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Results: Of the 21 patients, 5 (24%) had mediastinal nodal involve-
ment in different areas on PET compared to CT. In three patients, there 
were less nodal stations involved on PET vs. CT (stations 10, 5, 7; 
4R and 4L, respectively); in two patients, PET identiﬁed CT-negative 
mediastinal stations (station 5 and 7, respectively). PET based planning 
thus resulted in an increased nodal GTV in 2 patients and a decrease in 
3 patients. Taken all patients together, however, there were no signiﬁ-
cant differences in GTV, lung, and esophageal parameters between CT 
and PET-based plans. For CT vs. PET: V20 25.6±2.4 vs. 25.6±12.3 % 
(p=1.00); MLD: 13.7±5.6 vs. 13.7±5.6 Gy (p=0.89); MED: 24.4±8.6 
vs. 24.1±8.5 Gy (p=0.50); Dmax: 45.8± 2.9 vs. 45.7±2.9 Gy (p=0.32). 
For the three patients in whom the nodal GTV decreased with PET, the 
V20 decreased from 25.5± 4.9 to 22.0±7.1 % (p=0.10); MLD: 13.2±2.5 
vs. 11.6±3.3 Gy (p=0.10); MED: 25.0±8.5 vs. 21.0plusmn;5.7 Gy 
(p=0.10); Dmax: 46.2±0.21 vs. 45.5±0.71 Gy (p=0.32). 
Conclusions: Incorporating 18-FDG-PET information in radiotherapy 
planning in patients with LD-SCLC changed the treatment plan in 
24% of patients compared to CT. Both increases and decreases of the 
GTV were observed, theoretically leading to the avoidance of respec-
tively geographical miss or a decrease of radiation exposure of normal 
tissues. Based on these ﬁndings, a phase II trial, evaluating PET-scan 
based selective nodal irradiation is ongoing in our department. 
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Introduction: The role of surgery in treatment of pulmonary metasta-
ses remains controversial. The treatment strategy depends on localiza-
tion and histology of the primary tumor, its differentiation degree and 
number of metastases. Selective group of patients can beneﬁt from 
curative pulmonary metastasectomy. The purpose of our study was to 
evaluate the role of aggressive pulmonary metastasectomy as a part of 
multimodality approach.
Material and Methods: 412 consecutive patients with pulmonary me-
tastases of different origin were operated on in our clinic. The histology 
of the primary tumor: cancer of different origin - 268, sarcoma - 117 
and melanoma - 27. Solitary metastases were diagnosed in 236, 2-3 
metastases - in 80 and multiple - in 87 patients. Selection criteria for 
surgery were: local control of the primary tumor, metastases located in 
the lungs, except colorectal cancer patients, resistance to conservative 
therapy.
Results: We performed 487 operations in 412 patients. Wedge resec-
tion was performed in 225 (54,7%), lobectomy - in 118 (28,6%), 
precision technique - in 36 (8,7%), segmentectomy - in 10 (2,4%), 
pneumonectomy - in 23 (5,6%) patients. Thoracotomy approach was 
used in 389, sternotomy - in 3, thoracoscopic resection - in 20 patients. 
Postoperative mortality was 1,2%. Conservative therapy was admin-
istered in all patients with poor prognosis. Overall survivals at 5 years 
were 34,9% of patients with solitary metastases, 21,7% of patients with 
2-3 nodules and 14,7% of patients with multiple pulmonary metastases. 
Better 5-year survival was achieved after surgery of gynecological 
cancer (45,5%), renal cancer (40,2%), head and neck cancer (38,4%) 
and colorectal cancer (33,4%). The results decreases in breast cancer 
(31,6%) and soft-tissue sarcomas (32,5%). No one survived more than 
5 years after surgery for metastatic melanoma. Overall 5-year survival 
was 52,4% of patients with DFI>36 months versus 22,6% with DFI<36 
months. Five-year survival with negative lymph nodes was 36,2%, 
while with positive lymph nodes - 0%.
Conclusion: Surgery as a component of multimodality treatment is jus-
tiﬁed, because it helps to achieve 5-year survival in that complex group 
of patients. Localization and histology of the primary tumor, number of 
metastases, DFI and status of intrathoracic lymph nodes are the most 
important prognostic factors.
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We performed genome-wide array-based comparative genomic hybrid-
ization (CGH) analysis of malignant pleural mesotheliomas (MPMs) to 
identify regions that display DNA copy number alterations. Seventeen 
primary tumors and 9 cell lines derived from 22 individuals were stud-
ied. Regions of genomic aberrations observed in > 20% of individuals 
were 1q, 5p, 7p, 8q24, and 20p of gains, and 1p36.33, 1p36.1, 1p21.3, 
3p21.3, 4q22, 4q34-qter, 6q25, 9p21.3, 10p, 13q33.2, 14q32.13, 18q, 
and 22q of losses. Two regions at 1p32.1 and 11q22 showed a high 
copy gain. The 1p32.1 region contained a protooncogene, JUN, and we 
further demonstrated overexpression of JUN with real-time polymerase 
chain reaction (PCR) analysis. Since JUN overexpression was observed 
in primary tumors but not in cell lines, our ﬁndings suggested that 
induction of JUN expression was involved in the development of MPM 
cells in vivo, which also might result in gene ampliﬁcation in a subset 
of MPMs. We also analyzed the 11q21-23 ampliﬁcation region and 
found that YAP1 was located in this region. Meanwhile, the most fre-
quent alteration was the 9p21.3 deletion, which includes the p16INK4a/ 
p14ARF locus. With PCR analysis, we determined the extent of the 
homozygous deletion regions of the p16INK4a/ p14ARF locus in MPM 
cell lines, which indicated that the deletion regions varied among cell 
lines. Our results provide new insights into the genetic background of 
MPM, and also give some clues to manifest a new molecular target 
therapy for MPM.
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Background: Serum markers have been tested in patients with 
malignant effusions for their ability to differentiate malignant pleural 
mesothelioma from other causes. So far no single tumor marker has 
been identiﬁed that differentiates mesothelioma from other causes. 
We therefore combined three different serum markers and report our 
